| For: | Giri S, Mukhuty A, Mondal SA, Sahoo J, Roy A, Kamalanathan S, Naik D. Link between type 2 diabetes mellitus and hepatocellular carcinoma. World J Hepatol 2025; 17(7): 107675 [PMID: 40747219 DOI: 10.4254/wjh.v17.i7.107675] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v17/i7/107675.htm |
| Number | Citing Articles |
| 1 |
Qin Lou, Jiarong Cai, Jianhua Yin. Mechanisms and Management Strategies of Hepatocarcinogenesis Driven by Chronic Hepatitis B Comorbid with Type 2 Diabetes. Microorganisms 2026; 14(4) doi: 10.3390/microorganisms14040853
|
| 2 |
Mario Romeo, Fiammetta Di Nardo, Claudio Basile, Carmine Napolitano, Paolo Vaia, Luigi Di Puorto, Mattia Indipendente, Alessia De Gregorio, Marcello Dallio, Alessandro Federico. From FIB-4 to the Artificial Intelligence Era: The Evolution of Non-Invasive Tools (NITs) for Tailored Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Livers 2026; 6(4) doi: 10.3390/livers6040071
|
| 3 |
Amedeo Lonardo, Ralf Weiskirchen. The Liver Left Behind: GLP-1 Receptor Agonists and the Prospect of Metabolic Adjuvant Therapy After HCC Resection. Metabolites 2026; 16(7) doi: 10.3390/metabo16070499
|
| 4 |
Mirjana Grocic, Madison Nguyen, Arun J. Sanyal. Current Trends in the Epidemiology of Obesity and the Association Between Obesity and Metabolic Liver Disease (MASLD/MASH). Diabetes, Obesity and Metabolism 2026; 28(S2) doi: 10.1111/dom.70662
|
| 5 |
Seoung Hoon Kim. New-onset diabetes and pancreatic cancer: Current evidence on absolute risk and screening feasibility. World Journal of Gastrointestinal Oncology 2026; 18(7): 121817 doi: 10.4251/wjgo.v18.i7.121817
|
| 6 |
Xiaoli Yang, Peng Fu, Hui Liu. Association between metabolic risk factors and hepatocellular carcinoma: a systematic review and meta-analysis of cohort studies. Frontiers in Medicine 2026; 13 doi: 10.3389/fmed.2026.1865521
|